Alpha-Lipoic Acid

The VerdictMODERATE CONVICTIONWorth-It: Solid ROI (72/100)

Alpha-lipoic acid genuinely works for diabetic nerve pain and as a metabolic-disease adjunct.

Check the bottle in your hand. If it says "R-ALA" or "sodium R-lipoate" you're paying double for a chart, not a result. Switch to plain racemic alpha-lipoic acid 600 mg. Same evidence, half the price.

ALA works at 600 mg per day for diabetic peripheral neuropathy symptoms — burning, paresthesia, numbness. Five independent meta-analyses confirm it. This is the cleanest indication.
The "R-ALA is significantly better than racemic" pitch has zero clinical trials behind it. You pay 2× for a higher peak in the bloodstream, not better results.
Take 600 mg of plain racemic ALA on an empty stomach, 30 minutes before breakfast. About one capsule. Skip the £25/month "premium" forms.

That's the general answer. Your stack is different.

Check your whole stack

The Protocol

Population	Dose	Timing	Form	Duration
Diabetic peripheral neuropathy	600 mg/day	Empty stomach, 30 min before breakfast	Racemic	12+ weeks
T2D / metabolic disease adjunct	600–1,200 mg/day in 2–3 divided doses	Empty stomach, before meals	Racemic	≥8 weeks
Idiopathic male infertility (with supervision)	600 mg/day	Empty stomach	Racemic	12 weeks
Endothelial dysfunction (cardiometabolic)	300–600 mg/day	Empty stomach	Racemic	≥8 weeks
Healthy adult prophylactic	NOT RECOMMENDED	—	—	Evidence does not support

Forms — head-to-head

Racemic ALA

~30% bioavailable

What every clinical trial used. The default.

£8–15 / month at 600 mg/day

R-ALA

30–40% higher Cmax than racemic

Marketed as superior. No outcome RCT confirms it beats racemic on any endpoint.

£15–25 / month — pay 2× for a chart

Sodium R-α-lipoate

Higher Cmax in PK studies

Premium upgrade with zero clinical outcome trials.

£25–40 / month — skip

Intravenous (Thioctacid)

100% bypasses GI

Hospital-only DPN protocols (ALADIN trials). Prescription drug in Germany.

Clinic infusion cost

Absorption tips

Empty stomach is non-negotiable. Food reduces absorption ~30%. Take 30 minutes before breakfast.
Plasma half-life is ~30 minutes. Once-daily produces a transient spike. For glycemic and inflammatory indications, divide into 2–3 daily doses.
Separate from mineral supplements (iron, calcium, magnesium) by ≥2 hours. ALA chelates transition metals.
Separate from levothyroxine by ≥4 hours. Theoretical chelation reduces thyroid hormone absorption.

Safety & Interactions

Insulin Autoimmune Syndrome (IAS / Hirata disease) SEVERE

Anti-insulin antibodies producing severe spontaneous hypoglycemia. Strongly associated with HLA-DRB1*04:06, predominantly in Japanese, Korean, and some Chinese cohorts. Discontinue immediately and seek anti-insulin antibody workup if unexplained hypoglycemia occurs.

Insulin and sulfonylureas (glipizide, glyburide), metformin MODERATE

Additive blood-glucose lowering. In tightly-controlled T2D, hypoglycemia risk rises. Monitor blood glucose more frequently; physician should reassess hypoglycemic medication dose.

Levothyroxine MODERATE

Theoretical chelation reducing thyroid hormone absorption. Separate dosing by at least 4 hours.

Iron, calcium, magnesium supplements MILD

ALA chelates transition metals. Separate dosing by at least 2 hours (Sharifi-Zahabi 2024 iron homeostasis SR/MA).

Active chemotherapy / radiotherapy CAUTION

ALA has been studied as a chemoprotective adjunct (preclinical and small clinical signal). May also interfere with intended cytotoxicity. Oncology consult required before use during active treatment.

Contraindicated populations

Pregnant or lactating women — no adequately powered safety trials. Avoid by absence of data.
Children and adolescents — no adult-evidence-base extension data.
Patients of Asian descent with HLA-DRB1*04:06 risk profile or unexplained spontaneous hypoglycemia — IAS risk genotype.
Active cancer treatment — oncology consult before use.

Side effects

Gastrointestinal upset (nausea, abdominal discomfort) — most common AE in trials, dose-related. Worsens above 1,200 mg/day.
Skin rash, urticaria — uncommon. Discontinue if it occurs.
Hypoglycemia in diabetics on insulin/sulfonylureas — manageable with monitoring and prescriber oversight.

Upper limit

No formal Tolerable Upper Intake Level set by EFSA or NIH/ODS. Practical observed safety ceiling is 1,200 mg/day for long-term oral use (Carbonelli 2020 retrospective cohort). Trial-tested ceiling is 1,800 mg/day in DPN with rising GI side effects and no proportionate benefit gain above 600 mg/day.

MODERATE — overall, endpoint-stratified

How confident are we?

Per-endpoint conviction tells the real story. Diabetic peripheral neuropathy symptoms at 600 mg/day oral and HOMA-IR/insulin sensitivity in established metabolic disease are HIGH. HbA1c reduction in T2D, lipid profile, inflammatory biomarkers, endothelial function (FMD), and idiopathic male infertility sperm parameters are MODERATE. Weight loss as a standalone intervention, schizophrenia adjunct, and oral DPN nerve conduction velocity recovery are LOW. Healthy overweight intermediate markers (Luo 2025 GRADE) and R-ALA outcome superiority over racemic are DEBUNKED-by-absence. Longevity and biological-age effects: NONE — no human RCT exists.

What would change this verdict?

For healthy-adult prophylactic anti-aging: a 5-year RCT of ≥2,000 healthy adults (40–65 yr) on 600 mg/day racemic ALA vs placebo, with primary endpoints of GrimAge/Horvath epigenetic-age progression and incident cardiovascular disease, showing ≥10% epigenetic-age slowing or ≥15% CV event reduction.

For R-ALA outcome superiority: a double-blind head-to-head RCT of ≥300 DPN patients on R-ALA vs racemic ALA at matched 600 mg/day for 24 weeks, with primary endpoint TSS change, showing ≥30% superior reduction in the R-ALA arm at p<0.01.

For weight loss: a 12-month RCT of ≥500 overweight adults on ALA 1,200 mg/day vs placebo, both arms standardised hypocaloric diet, with primary endpoint body fat mass via DXA, showing ≥3% absolute fat mass difference.

Worth Your Money?

Estimated cost £2–3 per week. Racemic ALA 600 mg/day, taken once daily on empty stomach. Skip the £15–40/month "premium" R-ALA and Na-R-ALA forms.

Worth it if You have diagnosed diabetic peripheral neuropathy with persistent burning or paresthesia despite glycemic optimisation, or you have established metabolic disease and your prescriber agrees on adjunct use alongside first-line therapy.

Lower priority if You're a healthy adult buying it for fat loss, anti-aging, or general antioxidant support. Direct that £8–25/month at protein, sleep quality, and consistent training first — those move the dial more than ALA does in your population.

Conditional Value

Key Sources

Hsieh RY, et al. (2023). Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review. Nutrients, 15(16):3634. N=1,242 across 10 RCTs. TSS dose-related improvement at 600/1,200/1,800 mg/day; null on NCS, VPT, NIS-LL.
Ziegler D, et al. (2004). Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med, 21(2):114-21. N=1,258 across 4 IV RCTs (ALADIN I, ALADIN III, SYDNEY, NATHAN II). 600 mg IV × 3 wks; TSS relative difference 24.1%. [VIATRIS-database-funded]
Han T, et al. (2012). A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol, 167(4):465-71. 15 RCTs, 300–600 mg/day IV. MNCV +4.63 m/s; SNCV +3.17 m/s.
Akbari M, et al. (2018). The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases. Metabolism, 87:56-69. 24 RCTs in metabolic disease. HOMA-IR SMD −0.76; HbA1c SMD −1.22.
Mohammadi S, et al. (2026). Effects of alpha-lipoic acid supplementation on cardiometabolic risk factors. Nutr Metab Cardiovasc Dis. N=63 RCTs. HOMA-IR WMD −0.74; HbA1c −0.40%; FBG −5.28 mg/dL.
Luo Y, et al. (2025). Alpha-lipoic acid on intermediate disease markers in overweight or obese adults. BMJ Open. N=704 across 11 RCTs. NO significant effect on intermediate disease markers. GRADE-assessed.
Prado MB Jr, Adiao KJB. (2024). Ranking ALA and GLA for Diabetic Peripheral Neuropathy. Can J Diabetes. ALA 600 SMD −1.05.
Pires IZ, et al. (2025). Efficacy of Alpha Lipoic Acid Supplementation in Sperm Parameters. Int Braz J Urol. N=250 across 5 RCTs in idiopathic male infertility. GRADE certainty MODERATE.
Hajizadeh-Sharafabad F, Sharifi Zahabi E. (2022). Role of alpha-lipoic acid in vascular function. Crit Rev Food Sci Nutr. 12 trials. 10/11 endothelial function trials positive.
Mousavi SM, et al. (2019). Effect of alpha-lipoic acid supplementation on lipid profile. Nutrition. N=452 across 11 RCTs. TG WMD −29.2 mg/dL; TC −10.7; LDL −12.9; HDL NS.

Action ROI

Is this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.

Action ROI score

72/100 Solid ROI Trust grade B

Yes if you have diabetic nerve pain or metabolic disease, no for general antioxidant support or fat loss.

Time

Low

Money

Low

Effort

Medium

Risk

Medium

Why this score

Genuinely useful in the right population, which is exactly what this goal names: diabetic nerve-pain symptoms drop at 600 mg/day (Hsieh 2023, N=1,242), and insulin sensitivity improves in metabolic disease (HOMA-IR WMD -0.74, Mohammadi 2026, 63 RCTs; HbA1c about 0.40% absolute).
Cheap to run: racemic ALA is about $10 to $19 a month at 600 mg/day, and there is no real food source at therapeutic dose.
Effort is Medium, not Low: it has to be taken on an empty stomach 30 minutes before food, and its 30-minute half-life means 2 to 3 divided doses for the glycemic and inflammatory uses - real compliance friction.
Evidence grade is B: HIGH for nerve-pain symptoms and HOMA-IR in metabolic disease, but the 'antioxidant support' half of this goal is null in healthy adults (Luo 2025, N=704, GRADE), and oral ALA does not regenerate nerves - only eases symptoms.
Risk is Medium: it adds to the glucose-lowering of diabetes meds (hypoglycemia risk), and it can trigger Insulin Autoimmune Syndrome in HLA-DRB1*04:06 carriers, a rare but severe reaction concentrated in some Asian populations.

Why it didn’t score higher

It eases nerve symptoms but does not reverse nerve damage - oral trials are null on nerve conduction, vibration threshold, and NIS-LL (Hsieh 2023).
The 'antioxidant support' and fat-loss parts of this goal are null: weight loss is just 0.27 to 1.27 kg over 8 to 24 weeks, and healthy-adult markers do not move.
Empty-stomach timing plus divided dosing is real friction, and the hypoglycemia and Insulin Autoimmune Syndrome signals keep risk at Medium.

Best for

Adults with diagnosed diabetic peripheral neuropathy, at 600 mg/day racemic on an empty stomach for 12+ weeks
Adults with established metabolic disease (type 2 diabetes, metabolic syndrome, NAFLD) using it as an adjunct to first-line therapy at 600 to 1,200 mg/day under a prescriber
Men with idiopathic infertility under reproductive-medicine supervision, at 600 mg/day for 12 weeks

Lower ROI if

You are a healthy adult buying it for antioxidant insurance or fat loss - the GRADE-assessed evidence is null
You take it with food, losing roughly a third of the dose
You take it once daily, leaving the effective dose-time below trial conditions for glycemic uses
You are a diabetic on insulin or sulfonylureas without glucose monitoring, or an Asian-descent carrier with unexplained hypoglycemia history

Minimum effective dose

600 mg/day of racemic (regular) ALA on an empty stomach, 30 minutes before breakfast, for at least 12 weeks. Up to 1,200 mg/day in 2 to 3 divided doses for cardiometabolic adjunct use. No need to pay the R-ALA or sodium-R-ALA premium - the trials used racemic.

Track this

Nerve symptoms (burning, numbness, paresthesia) at baseline and week 12
HbA1c and fasting glucose at baseline and 12+ weeks if using it for metabolic disease
Blood glucose more frequently if you also take insulin or a sulfonylurea, to catch hypoglycemia